Literature DB >> 19950705

[Analysis of the survival in patients after surgical resection of thoracic esophageal cancer].

He-Lin Zhang1, Rui-Lin Liu, Yan-Tan Shi, Zhi-Chao Wang, Bao-Hua Wang, Yong-Jun Li, Lian-Ya Zhou, Yu-Min Ping.   

Abstract

OBJECTIVE: To investigate the prognostic factors and influence of the number of lymph node metastases on survival and UICC-TNM classification in patients with thoracic esophageal cancer after curative resection.
METHODS: From 1985 to 1990, 1224 patients were surgically treated for thoracic esophageal cancer. The patients who died within 30 days after operation were not included in this study. Fifteen factors possibly influencing survival of these patients were selected and analyzed. A multivariate analysis of these individual variables was performed by Cox proportional hazard model. According to the number of lymph node metastases (0, 1 and > or = 2), a new modification of the TNM classification was suggested: stage IIa (T2N0M0 and T3N0M0), stage IIb [T1N1M0 and T2N1(1)M0], stage IIIa [T2N1 (2)M0 and T3N1 (1) M0] and stage IIIb [T3N1 (2) M0 and T4N any M0].
RESULTS: According to multivariate analysis, lymph node metastases, depth of invasion, location of tumor, histological classification and length of the tumor were of prognostic significance (P < 0.01). There was obvious correlation between the rate of lymph node metastasis and the depth of invasion, length of tumor and grade of differentiation. The 5-year survival rate of the patients with 0, 1 and > or = 2 positive metastatic lymph nodes was 59.1%, 32.0% and 8. 9%, respectively. The 5-year survival rate of the patients with stage T2N1 M0 and stage T3N1 M0 was significantly higher in those with only one lymph node involved than in those with two or more lymph nodes involved (43.1% vs. 18.0% and 28.0% vs. 9.6%, P < 0.01). The 5-year survival rate of the modified stage IIa, IIb, IIIa and IIIb was 56.5%, 43.9%, 25.6% and 11.1%, respectively, with a statistically significant difference among different stages (P < 0.01).
CONCLUSION: The lymph node metastasis is the most important prognostic factor for thoracic esophageal cancer after resection. The major influencing factors of lymph node metastasis are the depth of invasion, length of tumor and grade of differentiation. Therefore, the lymphadenectomy along with esophagectomy and subsequently combined modality therapy against lymph node metastasis is necessary to improve the 5-year survival rate. Our proposed new classification based on number of lymph node metastases (0, 1, > or = 2 positive nodes) is more applicable because it can well reflect the correlation between lymph node metastasis and the survival, and provides evidence for the modification of the currently used UICC TNM staging system for surgically treated thoracic esophageal cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19950705

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  4 in total

1.  Demographic and histological predictors of survival in patients with gastric and esophageal carcinoma.

Authors:  Yousef Veisani; Ali Delpisheh; Kourosh Sayehmiri; Ezzatollah Rahimi
Journal:  Iran Red Crescent Med J       Date:  2013-07-05       Impact factor: 0.611

2.  Survival risk prediction model for patients with pT1-3 N0M0 esophageal squamous cell carcinoma after R0 esophagectomy with two-field lymphadenectomy for therapeutic purposes.

Authors:  Zhan Qi; Yuanping Hu; Rong Qiu; Juan Li; Yuekao Li; Ming He; Yuxiang Wang
Journal:  J Cardiothorac Surg       Date:  2021-05-01       Impact factor: 1.522

3.  Esophageal carcinoma: long-term survival in consecutive series of patients through a retrospective cohort study.

Authors:  Ali Delpisheh; Yousef Veisani; Kourosh Sayehmiri; Ezzatollah Rahimi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2014

4.  PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.

Authors:  Lin Wang; Ling Shan; Shaokai Zhang; Jianming Ying; Liyan Xue; Yanling Yuan; Yongqiang Xie; Ning Lu
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.